1887

Abstract

Fungi are increasingly recognised as major pathogens in critically ill patients. spp. and spp. are the yeasts most frequently isolated in clinical practice. The most frequent filamentous fungi (moulds) isolated are spp., but spp., spp., spp., and Zygomycetes are increasingly seen. Several reasons have been proposed for the increase in invasive fungal infections, including the use of antineoplastic and immunosuppressive agents, broad-spectrum antibiotics, and prosthetic devices and grafts, and more aggressive surgery. Patients with burns, neutropenia, HIV infection and pancreatitis are also predisposed to fungal infection. The epidemiology and clinical features of fungal infections are reviewed, together with antifungal agents currently or soon to be available.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46548-0
2006-07-01
2019-09-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/55/7/809.html?itemId=/content/journal/jmm/10.1099/jmm.0.46548-0&mimeType=html&fmt=ahah

References

  1. Ally, R., Schurmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P. & Romero, A. J., and the Esophageal Candidiasis Study Group ( 2001; ). A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33, 1447–1454.[CrossRef]
    [Google Scholar]
  2. Baddley, J. W., Pappas, P. G., Smith, A. C. & Moser, S. A. ( 2003; ). Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol 41, 5525–5529.[CrossRef]
    [Google Scholar]
  3. Barone, J. A., Moskovitz, B. L., Guarnieri, J., Hassell, A. E., Colaizzi, J. L., Bierman, R. H. & Jessen, L. ( 1998; ). Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 42, 1862–1865.
    [Google Scholar]
  4. Barrett, J. P., Vardulaki, K. A., Conlon, C. & 10 other authors ( 2003; ). A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 25, 1295–1320.[CrossRef]
    [Google Scholar]
  5. Becker, M. J., Lugtenburg, E. J., Cornelissen, J. J., Van Der Schee, C., Hoogsteden, H. C. & De Marie, S. ( 2003; ). Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 121, 448–457.[CrossRef]
    [Google Scholar]
  6. Bennett, J. E., Dismukes, W. E., Duma, R. J. & 12 other authors ( 1979; ). A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 301, 126–131.[CrossRef]
    [Google Scholar]
  7. Boogaerts, M., Winston, D. J., Bow, E. J. & 7 other authors, and the Itraconazole Neutropenia Study Group ( 2001; ). Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135, 412–422.[CrossRef]
    [Google Scholar]
  8. British Society for Antimicrobial Chemotherapy Working Party ( 1994; ). Management of deep Candida infection in surgical and intensive care unit patients. British Society for Antimicrobial Chemotherapy Working Party. Intensive Care Med 20, 522–528.[CrossRef]
    [Google Scholar]
  9. Caillot, D., Casasnovas, O., Bernard, A. & 10 other authors ( 1997; ). Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 15, 139–147.
    [Google Scholar]
  10. Caillot, D., Couaillier, J. F., Bernard, A. & 8 other authors ( 2001; ). Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19, 253–259.
    [Google Scholar]
  11. Carrillo, A. J. & Guarro, J. ( 2001; ). In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 45, 2151–2153.[CrossRef]
    [Google Scholar]
  12. Cornely, O. A., Ullmann, A. J. & Karthaus, M. ( 2003; ). Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101, 3365–3372.[CrossRef]
    [Google Scholar]
  13. Darras-Joly, C., Veber, B., Bedos, J. P., Gachot, B., Regnier, B. & Wolff, M. ( 1996; ). Nosocomial cerebral aspergillosis: a report of 3 cases. Scand J Infect Dis 28, 317–319.[CrossRef]
    [Google Scholar]
  14. Denning, D. W. ( 1998; ). Invasive aspergillosis. Clin Infect Dis 26, 781–803.[CrossRef]
    [Google Scholar]
  15. Denning, D. W. ( 2003; ). Echinocandin antifungal drugs. Lancet 362, 1142–1151.[CrossRef]
    [Google Scholar]
  16. Denning, D. W., Marinus, A., Cohen, J. & 11 other authors ( 1998; ). An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 37, 173–180.[CrossRef]
    [Google Scholar]
  17. Denning, D. W., Kibbler, C. C. & Barnes, R. A., and on behalf of the British Society for Medical Mycology ( 2003; ). British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 3, 230–240.[CrossRef]
    [Google Scholar]
  18. De Rosa, F. G., Shaz, D., Campagna, A. C., Dellaripa, P. E., Khettry, U. & Craven, D. E. ( 2003; ). Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 24, 477–482.[CrossRef]
    [Google Scholar]
  19. De Waele, J. J., Vogelaers, D., Blot, S. & Colardyn, F. ( 2003; ). Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 37, 208–213.[CrossRef]
    [Google Scholar]
  20. Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N. & Pfaller, M. A. ( 2003; ). Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41, 3623–3626.[CrossRef]
    [Google Scholar]
  21. Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N. & Wenzel, R. P. ( 1999; ). Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29, 239–244.[CrossRef]
    [Google Scholar]
  22. Eggimann, P., Garbino, J. & Pittet, D. ( 2003; ). Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3, 685–702.[CrossRef]
    [Google Scholar]
  23. Eriksson, U., Seifert, B. & Schaffner, A. ( 2001; ). Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 322, 579–582.[CrossRef]
    [Google Scholar]
  24. Goodman, J. L., Winston, D. J., Greenfield, R. A. & 7 other authors ( 1992; ). A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326, 845–851.[CrossRef]
    [Google Scholar]
  25. Hagerty, J. A., Ortiz, J., Reich, D. & Manzarbeitia, C. ( 2003; ). Fungal infections in solid organ transplant patients. Surg Infect (Larchmont) 4, 263–271.[CrossRef]
    [Google Scholar]
  26. Herbrecht, R., Denning, D. W., Patterson, T. F. & 19 other authors, for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group ( 2002; ). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347, 408–415.[CrossRef]
    [Google Scholar]
  27. Hughes, W. T., Armstrong, D., Bodey, G. P. & 8 other authors ( 2002; ). 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34, 730–751.[CrossRef]
    [Google Scholar]
  28. Husain, S., Alexander, B. D., Munoz, P. & 12 other authors ( 2003; ). Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 37, 221–229.[CrossRef]
    [Google Scholar]
  29. Johnson, L. B. & Kauffman, C. A. ( 2003; ). Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36, 630–637.[CrossRef]
    [Google Scholar]
  30. Johnson, E. M., Szekely, A. & Warnock, D. W. ( 1998; ). In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 42, 741–745.[CrossRef]
    [Google Scholar]
  31. Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E., Johnson, E. M., Perry, J. D., Sullivan, D. J. & Wilson, J. A. ( 2003; ). Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 54, 18–24.[CrossRef]
    [Google Scholar]
  32. Kontoyiannis, D. P., Hachem, R., Lewis, R. E. & 7 other authors ( 2003; ). Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98, 292–299.[CrossRef]
    [Google Scholar]
  33. Kullberg, B. J., Sobel, J. D., Ruhnke, M. & 11 other authors ( 2005; ). Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366, 1435–1442.[CrossRef]
    [Google Scholar]
  34. Laverdiere, M., Hoban, D., Restieri, C. & Habel, F. ( 2002; ). In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50, 119–123.[CrossRef]
    [Google Scholar]
  35. Leenders, A. C., Daenen, S., Jansen, R. L. H. & 9 other authors ( 1998; ). Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103, 205–212.[CrossRef]
    [Google Scholar]
  36. Li, X., Brown, N., Chau, A. S., Lopez-Ribot, J. L. & 7 other authors ( 2004; ). Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 53, 74–80.
    [Google Scholar]
  37. Maertens, J., Raad, I., Petrikkos, G. & 10 other authors, for the Caspofungin Salvage Aspergillosis Study Group ( 2004; ). Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39, 1563–1571.[CrossRef]
    [Google Scholar]
  38. Maertens, J., Theunissen, K., Verhof, G. & 7 other authors ( 2005; ). Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41, 1242–1250.[CrossRef]
    [Google Scholar]
  39. Manuel, R. J. & Kibbler, C. C. ( 1998; ). The epidemiology and prevention of invasive aspergillosis. J Hosp Infect 39, 95–109.[CrossRef]
    [Google Scholar]
  40. Marr, K. A., Seidel, K., Slavin, M. A., Bowden, R. A., Schoch, H. G., Flowers, M. E., Corey, L. & Boeckh, M. ( 2000; ). Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96, 2055–2061.
    [Google Scholar]
  41. Marr, K. A., Carter, R. A., Crippa, F., Wald, A. & Corey, L. ( 2002; ). Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34, 909–917.[CrossRef]
    [Google Scholar]
  42. Marr, K. A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, S. A., Nichols, W. G., Musher, B. & Corey, L. ( 2004; ). Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103, 1527–1533.
    [Google Scholar]
  43. Marty, F. M., Cosimi, L. A. & Baden, L. R. ( 2004; ). Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350, 950–952.[CrossRef]
    [Google Scholar]
  44. Mehrad, B., Paciocco, G., Martinez, F. J., Ojo, T. C., Iannettoni, M. D. & Lynch, J. P., 3rd ( 2001; ). Spectrum of Aspergillus infection in lung transplant recipients: case series and review of the literature. Chest 119, 169–175.[CrossRef]
    [Google Scholar]
  45. Mellinghoff, I. K., Winston, D. J., Mukwaya, G. & Schiller, G. J. ( 2002; ). Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 34, 1648–1650.[CrossRef]
    [Google Scholar]
  46. Mora-Duarte, J., Betts, R., Rotstein, C. & 7 other authors, for the Caspofungin Invasive Candidiasis Study Group ( 2002; ). Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347, 2020–2029.[CrossRef]
    [Google Scholar]
  47. Morgenstern, G. R., Prentice, A. G., Prentice, H. G., Ropner, J. E., Schey, S. A. & Warnock, D. W., on behalf of the UK Multicentre Antifungal Prophylaxis Study Group ( 1999; ). A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 105, 901–911.[CrossRef]
    [Google Scholar]
  48. Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G. & 9 other authors ( 2003; ). Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47, 3149–3154.[CrossRef]
    [Google Scholar]
  49. Ostrosky-Zeichner, L., Kontoyiannis, D. P., Raffalli, J. & 10 other authors ( 2005; ). International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24, 654–661.[CrossRef]
    [Google Scholar]
  50. Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J. & Edwards, J. E., on behalf of the Infectious Diseases Society of America ( 2004; ). Guidelines for treatment of candidiasis. Clin Infect Dis 38, 161–189.[CrossRef]
    [Google Scholar]
  51. Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., Hollis, R. J. & Jones, R. N., and the International Fungal Surveillance Participant Group ( 2003; ). In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 41, 78–83.[CrossRef]
    [Google Scholar]
  52. Phillips, P., Shafran, S., Garber, G. & 9 other authors, and for the Canadian Candidemia Study Group ( 1997; ). Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 16, 337–345.[CrossRef]
    [Google Scholar]
  53. Rex, J. H., Bennett, J. E., Sugar, A. M. & 9 other authors, for the Candidemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group ( 1994; ). A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331, 1325–1330.[CrossRef]
    [Google Scholar]
  54. Rex, J. H., Pappas, P. G., Karchmer, A. W. & 32 other authors, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group ( 2003; ). A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36, 1221–1228.[CrossRef]
    [Google Scholar]
  55. Ribes, J. A., Vanover-Sams, C. L. & Baker, D. J. ( 2000; ). Zygomycetes in human disease. Clin Microbiol Rev 13, 236–301.[CrossRef]
    [Google Scholar]
  56. Roilides, E., Dignani, M. C., Anaissie, E. J. & Rex, J. H. ( 1998; ). The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Med Mycol 36, 12–25.
    [Google Scholar]
  57. Rubin, M. A., Carroll, K. C. & Cahill, B. C. ( 2002; ). Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 34, 1160–1161.[CrossRef]
    [Google Scholar]
  58. Saag, M. S., Cloud, G. A., Graybill, J. R. & 11 other authors, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group ( 1999; ). A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 28, 291–296.[CrossRef]
    [Google Scholar]
  59. Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D. & Dismukes, W. E., for the Mycoses Study Group Cryptococcal Subproject ( 2000; ). Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 30, 710–718.[CrossRef]
    [Google Scholar]
  60. Schwartz, S., Behre, G., Heinemann, V. & 12 other authors ( 1999; ). Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 93, 3654–3661.
    [Google Scholar]
  61. Singh, N., Avery, R. K., Munoz, P. & 10 other authors ( 2003; ). Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 36, 46–52.[CrossRef]
    [Google Scholar]
  62. Slain, D., Rogers, P. D., Cleary, J. D. & Chapman, S. W. ( 2001; ). Intravenous itraconazole. Ann Pharmacother 35, 720–729.[CrossRef]
    [Google Scholar]
  63. Slavin, M. A., Osborne, B., Adams, R., Levenstein, M. J., Schoch, H. G., Feldman, A. R., Meyers, J. D. & Bowden, R. A. ( 1995; ). Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J Infect Dis 171, 1545–1552.[CrossRef]
    [Google Scholar]
  64. Steinbach, W. J., Stevens, D. A. & Denning, D. W. ( 2003; ). Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 37, S188–S224.[CrossRef]
    [Google Scholar]
  65. Stevens, D. A., Kan, V. L., Judson, M. A. & 7 other authors ( 2000; ). Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30, 696–709.[CrossRef]
    [Google Scholar]
  66. Sun, Q. N., Fothergill, A. W., McCarthy, D. I., Rinaldi, M. G. & Graybill, J. R. ( 2002; ). In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 46, 1581–1582.[CrossRef]
    [Google Scholar]
  67. Tobon, A. M., Arango, M., Fernandez, D. & Restrepo, A. ( 2003; ). Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 36, 1488–1491.[CrossRef]
    [Google Scholar]
  68. Torres, H. A., Hachem, R. Y., Chemaly, R. F., Kontoyiannis, D. P. & Raad, II ( 2005; ). Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 5, 775–785.[CrossRef]
    [Google Scholar]
  69. Tortorano, A. M., Biraghi, E., Astolfi, A. & 8 other authors, and the FIMUA Candidemia Study Group ( 2002; ). European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 51, 297–304.[CrossRef]
    [Google Scholar]
  70. Tortorano, A. M., Caspani, L., Rigoni, A. L., Biraghi, E., Sicignano, A. & Viviani, M. A. ( 2004a; ). Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect 57, 8–13.[CrossRef]
    [Google Scholar]
  71. Tortorano, A. M., Peman, J., Bernhardt, H. & 8 other authors, and the ECMM Working Group on Candidaemia ( 2004b; ). Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23, 317–322.[CrossRef]
    [Google Scholar]
  72. Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A. & Gaynes, R. P., and the National Nosocomial Infections Surveillance System Hospitals ( 2002; ). Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35, 627–630.[CrossRef]
    [Google Scholar]
  73. Vardakas, K. Z., Michalopoulos, A. & Falagas, M. E. ( 2005; ). Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 131, 22–28.[CrossRef]
    [Google Scholar]
  74. Vermes, A., Guchelaar, H. J. & Dankert, J. ( 2000; ). Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46, 171–179.[CrossRef]
    [Google Scholar]
  75. Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J. & Sable, C. A. ( 2001; ). A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 33, 1529–1535.[CrossRef]
    [Google Scholar]
  76. Villanueva, A., Gotuzzo, E., Arathoon, E. G., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J. & Sable, C. A. ( 2002; ). A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113, 294–299.[CrossRef]
    [Google Scholar]
  77. Walsh, T. J., Finberg, R. W., Arndt, C. & 9 other authors ( 1999; ). Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340, 764–771.[CrossRef]
    [Google Scholar]
  78. Walsh, T. J., Pappas, P., Winston, D. J. & 20 other authors, for the National Institute of Allergy and Infectious Diseases Mycoses Study Group ( 2002; ). Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346, 225–234.[CrossRef]
    [Google Scholar]
  79. Walsh, T. J., Teppler, H., Donowitz, G. R. & 8 other authors ( 2004; ). Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351, 1391–1402.[CrossRef]
    [Google Scholar]
  80. White, M. H., Bowden, R. A., Sandler, E. S. & 9 other authors ( 1998; ). Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27, 296–302.[CrossRef]
    [Google Scholar]
  81. Wingard, J. R., White, M. H., Anaissie, E., Raffalli, J., Goodman, J. & Arrieta, A., and the L Amph/ABLC Collaborative Study Group ( 2000; ). A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31, 1155–1163.[CrossRef]
    [Google Scholar]
  82. Winston, D. J., Pakrasi, A. & Busuttil, R. W. ( 1999; ). Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131, 729–737.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46548-0
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error